Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513383 · ClinicalTrials.gov registry record · Phase 1
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00513383: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00513383 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513383, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a type of drug called a monoclonal antibody that has been studied in other types of cancers, such as kidney and colon. This monoclonal antibody is directed against the epidermal growth factor receptor (EGFR). EGFR has been found on the majority of head and neck cancer cells. By blocking EGFR, this monoclonal antibody may inhibit the growth of head and neck cancer cells.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG 5-Fluorouracil
- RADIATION Intensity Modulated Radiation Therapy
- DRUG Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
What the finished NCT00513383 record still lists
NCT00513383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00513383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00513383 about?
NCT00513383 is a clinical study titled "Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck". This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a ...
What is the current status of trial NCT00513383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2006-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00513383?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), 5-Fluorouracil (DRUG), Intensity Modulated Radiation Therapy (RADIATION), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT00513383?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00513383's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia